ReproCELLorp (FRA:6RC) Total Equity: €45.31 Mil (As of Mar. 2026)


FRA:6RC ReproCELL Incorp FRA:6RC
57 GF Score
Price €0.49
GF Value €0.58
! 3 Warning Signs
View Full Analysis

What is ReproCELLorp Total Equity?

ReproCELLorp FRA:6RC +5.11% 57 Total Equity is €45.31 Mil as of Mar. 2026. GuruFocus rates FRA:6RC with a GF Score™ of 57/100 and a GF Value™ of €0.58. The stock has 3 warning signs investors should review.

ReproCELLorp's total equity for the quarter that ended in Mar. 2026 was €45.31 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ReproCELLorp Total Equity Historical Data

* Premium members only.

The historical data trend for ReproCELLorp's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ReproCELLorp Total Equity Chart

ReproCELLorp Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.52 52.93 51.04 55.76 45.31

ReproCELLorp Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.76 51.96 49.99 48.14 45.31
FRA:6RC
57GF Score
ReproCELL Incorp FRA:6RC
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ReproCELLorp Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ReproCELLorp's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=49.347-4.039
=45.31

ReproCELLorp's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=49.347-4.039
=45.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €45.31 Mil mean?
ReproCELLorp (FRA:6RC) has a Total Equity of €45.31 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ReproCELLorp and its competitors.
Is ReproCELLorp's Total Equity too high?
ReproCELLorp's current Total Equity is €45.31 Mil. Overall, ReproCELLorp has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does ReproCELLorp's Total Equity compare to VRTX and REGN?
ReproCELLorp's Total Equity of €45.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ReproCELLorp and its competitors. ReproCELLorp's current Total Equity is €45.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ReproCELLorp stock overvalued right now?
ReproCELLorp (FRA:6RC) has a current Total Equity of €45.31 Mil. The stock's GF Value™ is €0.58, compared to a current price of €0.49 — trading 14.8% below its estimated fair value. The current Total Equity is €45.31 Mil. ReproCELLorp's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ReproCELLorp (FRA:6RC), the current Total Equity is €45.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ReproCELLorp (FRA:6RC) Overvalued in 2026?

Based on GuruFocus' analysis, ReproCELLorp stock appears to be undervalued. The current stock price of €0.49 is trading 14.8% below its estimated GF Value™ of €0.58.

Key valuation signals for FRA:6RC:

  • Total Equity: €45.31 Mil
  • GF Value™: €0.58 vs. price of €0.49 (14.8% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the FRA:6RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ReproCELLorp Business Description

Other Exchanges 4978:Japan
Address KDX Shin-Yokohama 381 Bldg. 9F, 3-8-11, Shin-Yokohama, Kohoku-ku, Kanagawa, Yokohama, JPN, 222-0033
ReproCELL Incorp is one of the leading stem cell research company in Japan. The company provides stem cell services, predictive drug discovery services, tissue services, and molecular services.
57GF Score

Get the complete analysis for FRA:6RC

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price
€0.58
GF Value